View Future GrowthCVS Group 過去の業績過去 基準チェック /26CVS Groupは、平均年間1%の収益成長を遂げていますが、 Healthcare業界の収益は、年間 成長しています。収益は、平均年間4% 7.4%収益成長率で 成長しています。 CVS Groupの自己資本利益率は5.7%であり、純利益率は2.4%です。主要情報1.04%収益成長率0.78%EPS成長率Healthcare 業界の成長8.50%収益成長率7.43%株主資本利益率5.70%ネット・マージン2.38%次回の業績アップデート24 Sep 2026最近の業績更新お知らせ • Nov 14+ 1 more updateCVS Group plc to Report First Half, 2026 Results on Feb 26, 2026CVS Group plc announced that they will report first half, 2026 results on Feb 26, 2026お知らせ • Nov 16+ 1 more updateCVS Group plc to Report Fiscal Year 2025 Results on Sep 25, 2025CVS Group plc announced that they will report fiscal year 2025 results on Sep 25, 2025お知らせ • Dec 13+ 2 more updatesCVS Group plc to Report First Half, 2024 Results on Feb 29, 2024CVS Group plc announced that they will report first half, 2024 results on Feb 29, 2024お知らせ • Nov 12+ 2 more updatesCVS Group plc to Report Q4, 2023 Results on Sep 21, 2023CVS Group plc announced that they will report Q4, 2023 results on Sep 21, 2023すべての更新を表示Recent updatesお知らせ • May 14Converium Capital Sends Letter to CVS GroupOn May 13, 2026, Converium Capital Inc. announced that it has sent a letter to CVS Group Plc's Board of Directors highlighting the Company's undervaluation and urging the immediate initiation of a £100 million share buyback, equivalent to 12.5% of the Company's current market capitalization. In addition, Converium says a buyback is the highest-return use of capital currently available, the Company has capacity to fund it, and Converium stating that it remains available to discuss, and it is continuing its dialogue with other shareholders in the meantime.お知らせ • Apr 23Cvs Group plc Announces Appointment of Laura Hagan as Independent Non-Executive Director, Effective May 1, 2026CVS Group plc announced the appointment of Laura Hagan as an Independent Non-Executive Director with effect from May 1, 2026. Laura is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at FeverTree Drinks plc and was, until March 2026, Chief People Officer at Deliveroo plc. Laura's earlier executive roles include Chief People Officer at Gymshark Ltd, Chief HR Officer at Tate & Lyle plc and Group HR Director at Dyson Ltd. Laura has a wealth of experience in people leadership, organisation design optimisation, international expansion and the delivery of customer driven service through technology. Laura's blend of experience operating in both FTSE 250 and fast growth privately owned companies will add value to the board. From the date of her appointment, Laura will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. Laura's appointment, following that of Helen Keays and Jane Bednall announced on March 25, 2026, adds complementary skills and experience to the Board through her extensive listed company experience and her expertise in people development, leadership, customer service and international expansion.お知らせ • Mar 30+ 1 more updateCVS Group plc Announces Retirement of CEO Richard FairmanCVS Group plc announced that Richard Fairman has informed the Board of his intention to retire from his role as Chief Executive Officer for personal reasons. Richard will remain in post until a successor is appointed, to ensure an orderly transition, and he will continue to drive the business forward in the meantime. Since joining CVS in 2018 as CFO and assuming the role of CEO in 2019, Richard has led the Group through a period of significant strategic progress in support of its purpose to provide the best possible care to animals. Under Richard's leadership, CVS has built a culture centered on clinical excellence, strengthened its position as veterinary employer of choice and delivered sustainable growth alongside successful international expansion into the Australian market. During Richard's tenure, the Group has grown to approximately 9,000 employees including approximately 2,500 vets and 3,300 veterinary nurses and patient care assistants across approximately 475 practices and EBITDA has nearly tripled. Richard also guided the business through to the conclusion of the CMA process and, during the same period, oversaw the Group's step-up to the Main Market of the London Stock Exchange and its subsequent inclusion into the FTSE 250 index.お知らせ • Mar 25CVS Group plc Announces Board and Committee ChangesCVS Group plc announced the appointment of Helen Keays and Jane Bednall as Independent Non-Executive Directors with effect from 1 April 2026, the retirement of Deborah Kemp with effect from 30 June 2026 and a change in Chair of the Group's Nomination Committee. Deborah Kemp, who joined the board in January 2018 and who is presently Senior Independent Director and Chair of the Remuneration Committee will retire and step down from the Board and all board committees on 30 June 2026. Helen Keays is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at Nichols plc following an executive career in consumer-facing multi-site businesses across retail, mobile telecommunications and retail financial services. Helen has worked at Vodafone plc, latterly as General Manager of Singlepoint, and previously at Sears plc. Helen has previously been an Independent Non-Executive Director of The Restaurant Group, Domino's Pizza UK & Ireland, Communisis plc, Majestic Wine plc, Mattioli Woods plc and Chrysalis Group plc. Helen is an experienced Non-Executive Director and Remuneration Committee Chair and will add value to the board through her expertise in people development, consumer marketing and CRM. From the date of her appointment, Helen Keays will become Chair Designate of the Remuneration Committee and will also become a member of the Group's Audit and Risk Committee and Nomination Committee. Helen will formally become Chair of the Remuneration Committee with effect from 1 July 2026. Jane Bednall is presently an Independent Non-Executive Director of Fuller Smith & Turner plc and Independent Non-Executive Director and Chair of the Remuneration, People and Culture Committee for The Kings Cross Group, appointed on behalf of AustralianSuper, Australia's largest pension fund. This follows an executive career in senior leadership roles at British Airways, InterContinental Hotel Group (IHG), Centrica and most recently SSE plc where she was Chief Marketing Officer and formerly Managing Director of Retail Energy. Jane was previously Non-Executive Director of DFS plc, EI Group plc and Smart Energy GB. Jane will add value to the board through her experience in multi-site retail and leisure businesses and her expertise in branding, consumer behaviour and insights. From the date of her appointment, Jane will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. David Wilton, Chair of CVS, will succeed Richard Gray as Chair of the Nominations Committee with effect from 1 April 2026.お知らせ • Nov 14+ 1 more updateCVS Group plc to Report First Half, 2026 Results on Feb 26, 2026CVS Group plc announced that they will report first half, 2026 results on Feb 26, 2026お知らせ • Oct 24CVS Group plc (AIM:CVSG) announces an Equity Buyback for £20 million worth of its shares.CVS Group plc (AIM:CVSG) announces an share repurchase program. Under the program, the company will repurchases up to £20 million. The purpose of the Share Buyback Program is to both return surplus capital to shareholders and reduce the Group's share capital pursuant to its capital allocation policy. As such, all Ordinary Shares repurchased by the Group under the Share Buyback Program will be cancelled. The program will valid till Q1 of calendar year 2026.お知らせ • Oct 08+ 1 more updateCVS Group plc Recommends Final Dividend for the Year 2025, Payable on 5 December 2025The Board of CVS Group plc recommends the payment of a final dividend of 8.5p per Ordinary share (2024: 8.0p), subject to shareholder approval at the Annual General Meeting to be held on 18 November 2025. The ex-dividend date is 6 November 2025, the record date is 7 November 2025 and the dividend payment date is 5 December 2025.お知らせ • May 20Anima Care UK Limited acquired Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million.Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services. For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million. The expected completion date of the transaction is within the next five weeks. Anima Care UK Limited completed the acquisition of Crematoria operations of CVS Group plc (AIM:CVSG) on May 19, 2025. In related transaction, CVS Group plc completed the acquisition of VPP Group. Christopher Golden, James Steel and Andrew Clark of Peel Hunt LLP acted as financial advisor for CVS Group plc. Toby Flaux, Michael Burke, James Thompson and Milo Bonser brokered the transaction.お知らせ • Apr 25Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million.Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services. For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million. The expected completion date of the transaction is within the next five weeks.お知らせ • Nov 20CVS Group plc Proposes Final Dividend, Payable on 29 November 2024Subject to shareholder approval at the AGM, CVS Group plc intends to pay its previously announced final dividend of 8.0 pence per ordinary share on 29 November 2024 to holders on the register as at 1 November 2024. The ex-dividend date was 31 October 2024.お知らせ • Nov 16+ 1 more updateCVS Group plc to Report Fiscal Year 2025 Results on Sep 25, 2025CVS Group plc announced that they will report fiscal year 2025 results on Sep 25, 2025お知らせ • Jun 19CVS Group plc Announces Resignation of Ben Jacklin as Executive DirectorCVS Group plc announces that Ben Jacklin, Executive Director, has resigned. Ben's managerial and operational responsibilities, including the provision of clinical guidance to the Board, have been assumed by other senior members of the Group.お知らせ • May 01CVS Group plc Announces Board ChangesCVS Group plc announced the appointment of David Wilton as Chair with effect from 1 May 2024. David has served as an Independent Non-executive Director of the Company since September 2021. David is a qualified Chartered Accountant with more than 30 years' post-qualification experience as a Chief Financial Officer, Non-Executive Director (NED), Chair and consultant after many years in corporate finance, primarily in mid-cap M&A with Rothschilds. David has held roles in both public and private-equity backed companies including as CFO of Sumo Group plc, Group Finance Director of WYG plc and NED and Chair of the Audit Committee of Sweett Group plc. David was NED and subsequently Chair at Frontier Developments plc until November 2023. David is currently also NED and Chair Designate at Gateley (Holdings) plc. He has extensive experience of people businesses and of regulatory processes. David also brings to the Chair role a significant amount of technical expertise, which will support CVS in its strategic delivery of investment in technology. David Wilton's appointment follows a comprehensive search by the Nomination Committee, supported by a blue chip recruitment firm who sourced a number of high quality candidates. The Board would like to thank Deborah Kemp, the Group's Senior Independent Director who has been acting as Interim Chair during the search period. David will remain as Audit Committee Chair until this process is completed, at which point he will then step down as a member of the Audit Committee.お知らせ • Dec 13+ 2 more updatesCVS Group plc to Report First Half, 2024 Results on Feb 29, 2024CVS Group plc announced that they will report first half, 2024 results on Feb 29, 2024お知らせ • Oct 27CVS Announce Director ChangesCVS announced that its Chair Richard Connell has taken the difficult decision to resign with immediate effect due to ill health. Deborah Kemp, the Group's Senior Independent Director will assume the role of Chair for the interim period whilst the Board commences a process to appoint a permanent successor.お知らせ • Sep 21CVS Group plc Recommends Final Dividend, Payable on 8 December 2023CVS Group plc recommends continuation of progressive dividend policy, with the payment of a final dividend of 7.5 pence per Ordinary share (2022: 7.0 pence). The ex-dividend date is 2 November 2023 and the dividend payment date is 8 December 2023.お知らせ • Nov 12+ 2 more updatesCVS Group plc to Report Q4, 2023 Results on Sep 21, 2023CVS Group plc announced that they will report Q4, 2023 results on Sep 21, 2023収支内訳CVS Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:CVSG.F 収益、費用、利益 ( )GBP Millions日付収益収益G+A経費研究開発費31 Dec 2569317227030 Sep 2568318218030 Jun 2567319210031 Dec 2465617207030 Sep 2464721201030 Jun 2463925196031 Dec 2361345180030 Sep 2360147174030 Jun 2358948167031 Mar 2359336179031 Dec 2257729181030 Sep 2256628178030 Jun 2255426174031 Mar 2254626167031 Dec 2153826159030 Sep 2152422159030 Jun 2151019158031 Mar 2148015152031 Dec 2044911145030 Sep 204389137030 Jun 204286128031 Mar 204329126031 Dec 1943613123030 Sep 1942111127030 Jun 194078131031 Mar 193867130031 Dec 183657129030 Sep 183469122030 Jun 1832711116031 Mar 1831410110031 Dec 1730010105030 Sep 172861198030 Jun 172721291031 Mar 172591192031 Dec 162471092030 Sep 16232886030 Jun 16218780031 Mar 16202774031 Dec 15186668030 Sep 15177665030 Jun 151677610質の高い収益: CVSG.Fは 高品質の収益 を持っています。利益率の向上: CVSG.Fの現在の純利益率 (2.4%)は、昨年(2.5%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: CVSG.Fの収益は過去 5 年間で年間1%増加しました。成長の加速: CVSG.Fは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: CVSG.Fは過去 1 年間で収益成長率がマイナス ( -1.2% ) となったため、 Healthcare業界平均 ( 17% ) と比較することが困難です。株主資本利益率高いROE: CVSG.Fの 自己資本利益率 ( 5.7% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 07:27終値2026/04/17 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CVS Group plc 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13 アナリスト機関Sharanya GajapathyBarclaysJames BaylissBerenbergAllan SmylieDavy10 その他のアナリストを表示
お知らせ • Nov 14+ 1 more updateCVS Group plc to Report First Half, 2026 Results on Feb 26, 2026CVS Group plc announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Nov 16+ 1 more updateCVS Group plc to Report Fiscal Year 2025 Results on Sep 25, 2025CVS Group plc announced that they will report fiscal year 2025 results on Sep 25, 2025
お知らせ • Dec 13+ 2 more updatesCVS Group plc to Report First Half, 2024 Results on Feb 29, 2024CVS Group plc announced that they will report first half, 2024 results on Feb 29, 2024
お知らせ • Nov 12+ 2 more updatesCVS Group plc to Report Q4, 2023 Results on Sep 21, 2023CVS Group plc announced that they will report Q4, 2023 results on Sep 21, 2023
お知らせ • May 14Converium Capital Sends Letter to CVS GroupOn May 13, 2026, Converium Capital Inc. announced that it has sent a letter to CVS Group Plc's Board of Directors highlighting the Company's undervaluation and urging the immediate initiation of a £100 million share buyback, equivalent to 12.5% of the Company's current market capitalization. In addition, Converium says a buyback is the highest-return use of capital currently available, the Company has capacity to fund it, and Converium stating that it remains available to discuss, and it is continuing its dialogue with other shareholders in the meantime.
お知らせ • Apr 23Cvs Group plc Announces Appointment of Laura Hagan as Independent Non-Executive Director, Effective May 1, 2026CVS Group plc announced the appointment of Laura Hagan as an Independent Non-Executive Director with effect from May 1, 2026. Laura is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at FeverTree Drinks plc and was, until March 2026, Chief People Officer at Deliveroo plc. Laura's earlier executive roles include Chief People Officer at Gymshark Ltd, Chief HR Officer at Tate & Lyle plc and Group HR Director at Dyson Ltd. Laura has a wealth of experience in people leadership, organisation design optimisation, international expansion and the delivery of customer driven service through technology. Laura's blend of experience operating in both FTSE 250 and fast growth privately owned companies will add value to the board. From the date of her appointment, Laura will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. Laura's appointment, following that of Helen Keays and Jane Bednall announced on March 25, 2026, adds complementary skills and experience to the Board through her extensive listed company experience and her expertise in people development, leadership, customer service and international expansion.
お知らせ • Mar 30+ 1 more updateCVS Group plc Announces Retirement of CEO Richard FairmanCVS Group plc announced that Richard Fairman has informed the Board of his intention to retire from his role as Chief Executive Officer for personal reasons. Richard will remain in post until a successor is appointed, to ensure an orderly transition, and he will continue to drive the business forward in the meantime. Since joining CVS in 2018 as CFO and assuming the role of CEO in 2019, Richard has led the Group through a period of significant strategic progress in support of its purpose to provide the best possible care to animals. Under Richard's leadership, CVS has built a culture centered on clinical excellence, strengthened its position as veterinary employer of choice and delivered sustainable growth alongside successful international expansion into the Australian market. During Richard's tenure, the Group has grown to approximately 9,000 employees including approximately 2,500 vets and 3,300 veterinary nurses and patient care assistants across approximately 475 practices and EBITDA has nearly tripled. Richard also guided the business through to the conclusion of the CMA process and, during the same period, oversaw the Group's step-up to the Main Market of the London Stock Exchange and its subsequent inclusion into the FTSE 250 index.
お知らせ • Mar 25CVS Group plc Announces Board and Committee ChangesCVS Group plc announced the appointment of Helen Keays and Jane Bednall as Independent Non-Executive Directors with effect from 1 April 2026, the retirement of Deborah Kemp with effect from 30 June 2026 and a change in Chair of the Group's Nomination Committee. Deborah Kemp, who joined the board in January 2018 and who is presently Senior Independent Director and Chair of the Remuneration Committee will retire and step down from the Board and all board committees on 30 June 2026. Helen Keays is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at Nichols plc following an executive career in consumer-facing multi-site businesses across retail, mobile telecommunications and retail financial services. Helen has worked at Vodafone plc, latterly as General Manager of Singlepoint, and previously at Sears plc. Helen has previously been an Independent Non-Executive Director of The Restaurant Group, Domino's Pizza UK & Ireland, Communisis plc, Majestic Wine plc, Mattioli Woods plc and Chrysalis Group plc. Helen is an experienced Non-Executive Director and Remuneration Committee Chair and will add value to the board through her expertise in people development, consumer marketing and CRM. From the date of her appointment, Helen Keays will become Chair Designate of the Remuneration Committee and will also become a member of the Group's Audit and Risk Committee and Nomination Committee. Helen will formally become Chair of the Remuneration Committee with effect from 1 July 2026. Jane Bednall is presently an Independent Non-Executive Director of Fuller Smith & Turner plc and Independent Non-Executive Director and Chair of the Remuneration, People and Culture Committee for The Kings Cross Group, appointed on behalf of AustralianSuper, Australia's largest pension fund. This follows an executive career in senior leadership roles at British Airways, InterContinental Hotel Group (IHG), Centrica and most recently SSE plc where she was Chief Marketing Officer and formerly Managing Director of Retail Energy. Jane was previously Non-Executive Director of DFS plc, EI Group plc and Smart Energy GB. Jane will add value to the board through her experience in multi-site retail and leisure businesses and her expertise in branding, consumer behaviour and insights. From the date of her appointment, Jane will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. David Wilton, Chair of CVS, will succeed Richard Gray as Chair of the Nominations Committee with effect from 1 April 2026.
お知らせ • Nov 14+ 1 more updateCVS Group plc to Report First Half, 2026 Results on Feb 26, 2026CVS Group plc announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Oct 24CVS Group plc (AIM:CVSG) announces an Equity Buyback for £20 million worth of its shares.CVS Group plc (AIM:CVSG) announces an share repurchase program. Under the program, the company will repurchases up to £20 million. The purpose of the Share Buyback Program is to both return surplus capital to shareholders and reduce the Group's share capital pursuant to its capital allocation policy. As such, all Ordinary Shares repurchased by the Group under the Share Buyback Program will be cancelled. The program will valid till Q1 of calendar year 2026.
お知らせ • Oct 08+ 1 more updateCVS Group plc Recommends Final Dividend for the Year 2025, Payable on 5 December 2025The Board of CVS Group plc recommends the payment of a final dividend of 8.5p per Ordinary share (2024: 8.0p), subject to shareholder approval at the Annual General Meeting to be held on 18 November 2025. The ex-dividend date is 6 November 2025, the record date is 7 November 2025 and the dividend payment date is 5 December 2025.
お知らせ • May 20Anima Care UK Limited acquired Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million.Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services. For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million. The expected completion date of the transaction is within the next five weeks. Anima Care UK Limited completed the acquisition of Crematoria operations of CVS Group plc (AIM:CVSG) on May 19, 2025. In related transaction, CVS Group plc completed the acquisition of VPP Group. Christopher Golden, James Steel and Andrew Clark of Peel Hunt LLP acted as financial advisor for CVS Group plc. Toby Flaux, Michael Burke, James Thompson and Milo Bonser brokered the transaction.
お知らせ • Apr 25Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million.Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services. For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million. The expected completion date of the transaction is within the next five weeks.
お知らせ • Nov 20CVS Group plc Proposes Final Dividend, Payable on 29 November 2024Subject to shareholder approval at the AGM, CVS Group plc intends to pay its previously announced final dividend of 8.0 pence per ordinary share on 29 November 2024 to holders on the register as at 1 November 2024. The ex-dividend date was 31 October 2024.
お知らせ • Nov 16+ 1 more updateCVS Group plc to Report Fiscal Year 2025 Results on Sep 25, 2025CVS Group plc announced that they will report fiscal year 2025 results on Sep 25, 2025
お知らせ • Jun 19CVS Group plc Announces Resignation of Ben Jacklin as Executive DirectorCVS Group plc announces that Ben Jacklin, Executive Director, has resigned. Ben's managerial and operational responsibilities, including the provision of clinical guidance to the Board, have been assumed by other senior members of the Group.
お知らせ • May 01CVS Group plc Announces Board ChangesCVS Group plc announced the appointment of David Wilton as Chair with effect from 1 May 2024. David has served as an Independent Non-executive Director of the Company since September 2021. David is a qualified Chartered Accountant with more than 30 years' post-qualification experience as a Chief Financial Officer, Non-Executive Director (NED), Chair and consultant after many years in corporate finance, primarily in mid-cap M&A with Rothschilds. David has held roles in both public and private-equity backed companies including as CFO of Sumo Group plc, Group Finance Director of WYG plc and NED and Chair of the Audit Committee of Sweett Group plc. David was NED and subsequently Chair at Frontier Developments plc until November 2023. David is currently also NED and Chair Designate at Gateley (Holdings) plc. He has extensive experience of people businesses and of regulatory processes. David also brings to the Chair role a significant amount of technical expertise, which will support CVS in its strategic delivery of investment in technology. David Wilton's appointment follows a comprehensive search by the Nomination Committee, supported by a blue chip recruitment firm who sourced a number of high quality candidates. The Board would like to thank Deborah Kemp, the Group's Senior Independent Director who has been acting as Interim Chair during the search period. David will remain as Audit Committee Chair until this process is completed, at which point he will then step down as a member of the Audit Committee.
お知らせ • Dec 13+ 2 more updatesCVS Group plc to Report First Half, 2024 Results on Feb 29, 2024CVS Group plc announced that they will report first half, 2024 results on Feb 29, 2024
お知らせ • Oct 27CVS Announce Director ChangesCVS announced that its Chair Richard Connell has taken the difficult decision to resign with immediate effect due to ill health. Deborah Kemp, the Group's Senior Independent Director will assume the role of Chair for the interim period whilst the Board commences a process to appoint a permanent successor.
お知らせ • Sep 21CVS Group plc Recommends Final Dividend, Payable on 8 December 2023CVS Group plc recommends continuation of progressive dividend policy, with the payment of a final dividend of 7.5 pence per Ordinary share (2022: 7.0 pence). The ex-dividend date is 2 November 2023 and the dividend payment date is 8 December 2023.
お知らせ • Nov 12+ 2 more updatesCVS Group plc to Report Q4, 2023 Results on Sep 21, 2023CVS Group plc announced that they will report Q4, 2023 results on Sep 21, 2023